RGNT Regentis Biomaterials Ltd.
$1.80▼ -4.52%
Healthcare
Other
Volume 157.7K
Avg Volume (10D) 26.0K
Key Metrics & Fundamentals
Market Cap
$12.61M
P/E Ratio
–
Div Yield
–%
52W Range
1.23 - 15.50
% vs 50 MA
-15.15%
% vs 200 MA
–%
RSI-14
40.8
MACD Histogram
+0.0000
Beta (1Y vs SPY)
8.82
Gross Rev
–
Gross Profit
–
EBITDA
–
COGS
–
Operating Exp
–
Operating Income
–
EBIT
–
Pretax Income
–
Net Income
–
Price & Volume History
Loading chart…
Recent News
Regentis Biomaterials (RGNT) Advances GelrinC as a Potential New Approach to Knee Cartilage Repair
NewMediaWire · Sep 14, 2026 7:26 PM
Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
ACCESS Newswire · Sep 11, 2026 1:00 PM
Regenerative Hydrogel Is Redefining Cartilage Repair as Regentis Advances GelrinC
NewMediaWire · Aug 28, 2026 6:30 PM
Regentis Biomaterials (RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks
NewMediaWire · Aug 17, 2026 6:16 PM
Regentis Biomaterials (RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market
NewMediaWire · Aug 14, 2026 6:30 PM
Regentis Biomaterials (RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair
NewMediaWire · Aug 3, 2026 7:30 PM
Regentis Biomaterials (RGNT) Targets $3B Cartilage Repair Market with Cell-Free Gelrin C
NewMediaWire · Jul 30, 2026 7:30 PM
Regentis Biomaterials (RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3B Cartilage Repair Market
NewMediaWire · Jul 27, 2026 7:00 PM
Regentis Biomaterials Obtains Japanese Patent Allowance for Cartilage Repair Treatment
MT Newswires · Jul 20, 2026 1:37 PM
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
ACCESS Newswire · Jul 20, 2026 1:00 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
Social Sentiment
Avg -0.60 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.